La recherche avance, la vie progresse. MEDICINE AND HEALTH IN THE TROPICS Plenary Session 3 « The Pharmaceutical Industry’s R&D Drive and the issue of.

Slides:



Advertisements
Similar presentations
Diseases without borders What must the Global Development Community Do? World Bank Seminar Series Tawhid Nawaz, Operations Advisor Human Development Network.
Advertisements

Our vision is a world free from TB. Our mission is to address the health, social and economic impact of the global TB epidemic amongst vulnerable and.
Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.
10 FACTS ON NEGLECTED TROPICAL DISEASES Fact 1 More than 1 billion people are affected by one or more neglected tropical diseases (NTDs). They are named.
Critical conversations in Public-private partnerships Dr Ranjana Kumar 1 st November 2007.
The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.
Advance Market Commitments for Vaccines Carlo Monticelli International Financial Relations Ministero dell’Economia e delle Finanze.
WHO Roadmap for Neglected Tropical Diseases Department of Control of Neglected Tropical Diseases World Health Organization, Geneva All-Party Parliamentary.
The World Public Health at a Crossroad Guillermo Foladori CSPO Columbia University 2003 Meeting “The Uneven Evolution of Medical Know-how” Burden Room,
Towards an AIDS-Free Generation Women & Girls and HIV in PEPFAR
Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.
The Global Burden of Hepatitis C Dr Daniel Lavanchy World Health Organization (WHO) Geneva, Switzerland 3 rd Paris Hepatitis Conference.
NCI Center for Global Health Jo Anne Zujewski, M.D. September 11, 2014 Dar es Salaam, Tanzania.
The role of commercial enterprises in health Dr. Petra Laux, GSK Brussels September 2001.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Slide 2 Key Points Although HIV/AIDS is found throughout the world, most people living with HIV/AIDS reside in low- and middle-income countries More people.
Andrew Gray March 10, Poverty Basic nutrition and clean water Shelter Education Basic medical care (public health) Lack of access.
Did you know...  That one in every six people on this globe suffers from a disease of poverty?  That ten million people die each year from diseases.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
Managing Risk and Overcoming Health Systems Bottlenecks in Haiti Emerging Lessons Jessica Faieta - Senior Country-Director, UNDP/Haiti & Dr Joelle Deas.
The Value of Partnerships in Fighting HIV/AIDS in Romania: Bringing Children New Hope Jeffrey L. Sturchio Vice President, External Affairs Europe, Middle.
Total health ODA commitments, US$ Billions.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Call to governments: Boost innovation for neglected diseases Bernard Pécoul Executive Director MSF meeting 8 June 2005.
The Infectious Diseases Institute Kampala, Uganda InfoPoverty World Conference United Nations InfoPoverty World Conference United Nations Robert L. Mallett.
COUNTRY ACTION: SUSTAINABLE INVESTMENT STOP TB PARTNERSHIP FORUM STOP TB PARTNERSHIP FORUM 24TH-26TH MARCH TH-26TH MARCH 2004 BY BY MRS NENADI USMAN.
1 Patents and Public Health Dr. Eric Noehrenberg Director International Trade and Market Policy, IFPMA WIPO Open Forum on the draft SPLT, Geneva, 3 March.
1 |1 | Key problems Neglected Tropical Diseases Hidden and silent : Key problems Complacency, lack of information and commitment Complacency, lack of information.
Neglected Tropical Diseases: Control & Research
Nutrition/HIV – new developments Increased Evidence Base – e.g. micronutrient supplements, RUTF High Profile Meetings – Durban, Blantyre. Others planned.
Essential Medicines and the University Challenge: Promoting Local Research for Global Impact For more information, please visit: UAEM home page:
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Public-Private Partnerships -Selected Experiences in the Western Pacific & Cambodia- National Forum on Public-Private Partnership in Health 7 November,
Enabling Continuity of a Public Health ARV Treatment program in a resource limited setting: The Case of the transition of the African Comprehensive HIV/AIDS.
Svetlana Spassova, MD Ministry of Health, Bulgaria Chisinau
MEDICAL INNOVATION March What Are The Public Health Benefits of Medical Innovation? Breakthrough medicines New devices Innovative medical procedures.
MSF Access Campaign Started in 1999 Rooted in field experience Three Pillars: –Overcoming Barriers –Research and Development for Drugs for Neglected Diseases.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
© IFPMA 2009WIPO Open-ended Forum on Proposed Development Agenda Projects - 13/10/2009 IFPMA views on the strategic use of information for sustainable.
UN Millennium Development Goals Going on offense against HIV and malaria in Southern Africa.
Building the Capacity of the Health and Social Care System in Case Management J. Csiszar MD. MSc. MBA IAS Conference July 2010 “ HELP” HIV/AIDS Education.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Millions of people have a drug problem ! They can not get any !
XVII INTERNATIONAL AIDS CONFERENCE PANCAP Satellite Meeting Hon Douglas Slater, Minister of Health, St. Vincent and the Grenadines.
PROVIDA’S IMPACT ON IMPROVING ACCESS TO AND USE OF ESSENTIAL DRUGS IN POOR COMMUNITIES IN PERU JOSEFA CASTRO, PHARMACIST JORGE SOLARI, PHYSICIAN SERVICIO.
World Health Organization "3 by 5" Target Treat 3 million by 2005.
UCL Workshop Dr Mary Moran Policy Cures December 2014.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Alexandra Heumber Médecins Sans Frontières Access to Essential Medicines Campaign DEBRIEFING WHA May 2006.
Global Forum for Health Research Mumbai, September 12 to Rob Ridley Director, TDR Sustaining Priority Research for Neglected Tropical Diseases.
Meeting of the Working Group on TB Drug Development Why you need to be engaged? Marcos Espinal Executive Secretary Stop TB Partnership 29 October 2004.
Page 0 UNITAID’s Strategic Approach to HIV Diagnostics  Washington DC 22 July, 2012 XIX International AIDS Conference Brenda Waning.
Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.
WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.
Rethinking Health Innovation from the South WORKSHOP South Africa/ Cape town December 13 – 15 /2010.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.
REIMAGING PHARMACEUTICAL INNOVATION.
World Health Organization
APPMG December 17, 2008 Presented by Dr. John P. Rumunu (MPH, MB.BS)
Finland, a Global Testbed for Personalized Cancer Research?
Accessing Medicines in Africa Prospects and challenges
Neglected Tropical Diseases Hidden and silent : Key problems
Medicine in third world countries
Neglected Tropical Diseases Hidden and silent : Key problems
The Global Fund to Fight AIDS, Tuberculosis and Malaria
The STOP TB Strategy – 2009 VISION: A TB-free world
A Time of Commitments and Actions to accelerate action to End TB
GFAN Call: Briefing on the African Leadership Summit
Expert Speak: How Pharma Companies Can Grow Their Business?
Presentation transcript:

La recherche avance, la vie progresse. MEDICINE AND HEALTH IN THE TROPICS Plenary Session 3 « The Pharmaceutical Industry’s R&D Drive and the issue of Tropical diseases » 13 of September 2005 Dr Pierre Le Sourd Leem President Dr Pierre Le Sourd Leem President

La recherche avance, la vie progresse. 2 The issue of Tropical Diseases  Definition –« Neglected infectious diseases that disproportionately affect poor and marginalized populations » (TDR – Special Program for Research and Training in Tropical Diseases)  Current disease portfolio Source: World Health Report, 2004World Health Report, 2004 * DALYs - Disability Adjusted Life Years (the number of healthy years of life lost due to premature death and disability) TDR Disease Category: 1 – « Emerging or uncontrolled disease » 2 – « Control strategy available, but disease burden persists » 3 – « Control strategy effective / Elimination planned »

La recherche avance, la vie progresse. What is the Pharmaceutical Industry doing about it ?  Drug Companies part of the solution instead of the issue

La recherche avance, la vie progresse. 4 Medicines exist but don’t reach the patients in need Source: IFPMA, Septembre 2004 Most essential medicines are off-patent and inexpensive; however over 50 % of populations in Least Developed Countries lack regular access to these products

La recherche avance, la vie progresse. 5 What are the real barriers ?  Poverty  Lack of public health infrastructure  Lack of human resources  Lack of manufacturing capability  High tariffs on medicines  Political denial

La recherche avance, la vie progresse. 6 Successful interventions supported by Drug Companies (1)  In last decade, global companies have become critical contributors to numerous programs and initiatives targeting health needs of the poor  In 2003, the value of donations by major companies matched the US AID Global Budget for Health –3,7$ billion over last 5 years

La recherche avance, la vie progresse. 7 Successful interventions supported by Drug Companies (2)  Examples of concrete actions –Malaria  In 2001, Novartis formed a partnership with WHO to provide Coartem at no profit in developing countries  Sanofi-Aventis launched a Specific Program: « Impact Malaria » to develop new treatments, new therapeutic strategies, educational campaign and to provide drugs at price, « not loss, not profit »  Achievements: Pilot projects in South Africa resulted with outstanding health outcomes:  Malaria cases reduced by 86%  Hospital admissions for malaria reduced by 82%  Malaria deaths decreased by 87% –Tuberculosis  In South Africa, a huge involvement of Sanofi-Aventis Rifafour – a combination of 4 medicines –commercialized to enable better compliance A specific training program of 15$ million developed – DOT Supporters (DOT: Directly Observed Treatment) for Health agents  Ambitions:  Building of 9 Training centers  100,000 Health agents trained

La recherche avance, la vie progresse. 8 Successful interventions supported by Drug Companies (3)  Examples of concrete actions –Leishmaniasis  Ampules of Glucantime (Sanofi-Aventis) provided at no profit –Onchocerciasis  40 million doses of Mectizan (Merck) donated annually in 34 countries –Trachoma  16 million treatments donated in 11 countries  More than 80$ million of Zithromax (Pfizer) donated –Leprosy  35$ million donated in multi-drug treatment (Novartis)  Achievements: About 13 million people cured over the past 15 years, while some 2-3 million people have been protected from developing deformities –Lymphatic Filariasis  6 billion treatments of albendazole (GSK) planned to be donated  20 million treatments of Mectizan (Merck) donated  Achievements: 80 million people have received treatment

La recherche avance, la vie progresse. 9 Successful interventions supported by Drug Companies (4)  HIV/AIDS reference –To increase access to ARVs in developing countries, a huge involvement of the Pharmaceutical Industry  564$ million in 2002  Involvement in International Programs  ONUSIDA  ACCESS: thanks to significant price discounts, more than 330,000 patients in developing countries received ARVs by the end of September 2004  Pharmaceutical Initiatives  Determine Donation Program (Abott), Secure the Future (BMS), African Comprehensive HIV/Aids Partnership (Merck&Co), International HIV/Aids Health Literacy Grants Program (Pfizer)…  Health agents Training, equipments supply, prevention technical aids, health education

La recherche avance, la vie progresse. 10 New or improved treatments needed Source: IFPMA, Septembre 2004

La recherche avance, la vie progresse. 11 Drug resistance is widespread: the example of Malaria

La recherche avance, la vie progresse. 12 What about new drugs and vaccines ? (1)  Quantum leap in Research is coming –R&D is at a crossroad –Development of Biotech Products…  2003: 40% of New Molecular Entities  2010: around 100 New Molecular Entities expected –… could deliver major breakthroughs… –… leading to new hope for Tropical Diseases

La recherche avance, la vie progresse. 13 What about new drugs and vaccines ? (2)  New dynamics in R&D for Neglected Diseases –Establishment of dedicated research centers by major companies and increasing not-for-profit approach to R&D for neglected diseases –Creation of a R&D efforts database of IFPMA members –Growing number of product development public private partnerships (PPPs) –Proliferation of R&D players, including public research institutes, academia, major pharma companies, small specialized biopharmaceutical companies from developed and developing countries, etc.

La recherche avance, la vie progresse. 14 Establishment of Dedicated Research Centers Source: IFPMA, Septembre 2004

La recherche avance, la vie progresse. 15 Creation of a R&D efforts database  In September 2005, launch of a database collecting all the health initiatives involving the pharmaceutical industry to benefit the Developing countries –A comprehensive list of both R&D and Access Initiatives –Accessible on the Internet (via the IFPMA website) by the general public –Create an overall vision for industry activities in addressing developing countries needs –Build a central depositary used to create new collaborations and partnerships

La recherche avance, la vie progresse. 16 Public-Private Partnerships development (1)  TDR – The Special Program for Research and Training in Tropical Diseases - and its Industry Partner: a long and fruitful collaboration

La recherche avance, la vie progresse. 17 Public-Private Partnerships development (2)  Examples of Product Development PPPs for Neglected diseases Source: IFPMA, Septembre 2004

La recherche avance, la vie progresse. 18

La recherche avance, la vie progresse. 19 FAC Project: an innovative partnership against Malaria  For Malaria, new medicine needed to adress drug resistance –WHO recommands the development of 4 Artemisine Combination Therapies (ACT) : –But, 2 combinations needed a new fixed-dose combination  FAC Project: –A scientific partnership, coordinated by DNDi, to develop fixed- dose combination of Artesunate/Amodiaquine (AS/AQ) and Artesunate/Mefloquine (AS/MQ) –A public-private Innovative partnership: Sanofi-Aventis & DNDi  In 2006, a new medicine available Easy to use for adults and children Less expensive: Target price 1$ Off patent  WHO estimations: 50 to 100 million of people could received this treatement

La recherche avance, la vie progresse. 20 Results: a growing R&D pipeline Source: IFPMA, Septembre 2004

La recherche avance, la vie progresse. 21 Conclusions  Public-private partnerships prove to offer the most effective solution  Pharmaceutical companies increasing its commitment in: –Developing dedicated R&D projects –Establishing many health partnerships –Bringing critical resources (products, money, people) –Contributing in valuable cross-country experience and expertise in health care delivery –Introducing a private sector management philosophy that helps achieve needed results  Significant and promising global awareness

La recherche avance, la vie progresse. 22 Conclusions  Therefore, any successful initiatives must include: –Political will –Partners –Infrastructure to get the medicines to patients –Physicians training and patient education –Proper diagnosis & dispensing –Quality control –Proper dispensing –Monitoring of outcomes